Solid Biosciences Inc. Common Stock (SLDB)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Solid Biosciences Inc. Common Stock (SLDB) is listed on Nasdaq, where it has traded since January 25, 2018.
- Listed On
- Nasdaq
- Listed Since
- January 25, 2018
- Employees
- 121
- Market Cap
- $695M
About Solid Biosciences Inc. Common Stock
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 152 institutions reported holding SLDB, with 114.5 million shares worth $1.1 billion in aggregate. The largest reported holder was RA Capital Management, with 12.0 million shares worth $120.2 million. Of the 5 largest holders listed below, 2 added shares and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| RA Capital Management | 12,036,126 | $120M | Added 28.87% |
| Perceptive Advisors | 11,906,646 | $119M | Unchanged |
| Bain Capital Life Sciences Investors | 9,808,819 | $98M | Unchanged |
| Siren | 7,690,405 | $77M | Unchanged |
| BlackRock | 6,934,248 | $69M | Added 39.85% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is SLDB?
Solid Biosciences Inc. Common Stock (SLDB) is listed on Nasdaq, where it has traded since January 25, 2018.
Who are the largest institutional holders of SLDB?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of SLDB were RA Capital Management, Perceptive Advisors and Bain Capital Life Sciences Investors.
How many institutions own SLDB?
152 institutions reported a position in SLDB for the quarter ended June 30, 2026, worth $1.1 billion in total.
Did institutions buy or sell SLDB last quarter?
Of the 5 largest reported holders, 2 added shares and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for SLDB.
Every reported institutional holder, plus insider and congressional trades in SLDB, on SentiSense.